Subcutaneously delivered natalizumab for the treatment of highly active relapsing-remitting multiple sclerosis

被引：0

作者：

Haluskova, S. ^{[1
]}

Valis, M. ^{[1
]}

机构：

[1] LF UK & FN Hradec Kralove, Neurol Klin, Sokolska 581, Hradec Kralove 50005, Czech Republic

来源：

CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE | 2022年 / 85卷 / 03期

关键词：

multiple sclerosis -; treatment; monoclonal antibodies; natalizumab; subcutaneous administration; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; DISEASE-ACTIVITY; EFFICACY; ANTIBODY; EVOLUTION; THERAPY; SAFETY;

D O I：

10.48095/cccsnn2022206

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Therapeutic monoclonal antibodies (MAbs) have become one of the fastest growing classes of drugs, approved for the treatment of a wide range of indications. The development of new humanized and fully human MAbs has vastly improved their safety profile. Natalizumab is a humanized anti-???4-integr in monoclonal antibody, indicated as a single disease modifying therapy in adults with highly active relapsing-remitting multiple sclerosis. In 2021, natalizumab was authorized for use also as a subcutaneous injection. Clinical trials have shown that monthly subcutaneous injections of natalizumab are as safe and clinically and radiologically effective as monthly intravenous infusions.

引用

页码：206 / 212

页数：7

共 38 条

[1]

[Anonymous], SOUHRN UDAJU PRIPRAV

[2]

[Anonymous], 2020, Atlas of MS, V3rd ed

[3] Extended interval dosing of natalizumab: a two-center, 7-year experience [J].

Bomprezzi, Roberto ;

Pawate, Siddharama .

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2014, 7 (05) :227-231

[4] Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP) [J].

Butzkueven, Helmut ;

Kappos, Ludwig ;

Wiendl, Heinz ;

Trojano, Maria ;

Spelman, Tim ;

Chang, Ih ;

Kasliwal, Rachna ;

Jaitly, Seema ;

Campbell, Nolan ;

Ho, Pei-Ran ;

Licata, Stephanie .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2020, 91 (06) :660-668

[5] Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every-4-Week Dosing to Extended-Interval Dosing [J].

Chang, Ih ;

Muralidharan, Kumar Kandadi ;

Campbell, Nolan ;

Ho, Pei-Ran .

JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (03) :339-348

[6] Natalizumab in Multiple Sclerosis: Long-Term Management [J].

Clerico, Marinella ;

Artusi, Carlo Alberto ;

Di Liberto, Alessandra ;

Rolla, Simona ;

Bardina, Valentina ;

Barbero, Pierangelo ;

De Mercanti, Stefania Federica ;

Durelli, Luca .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (05)

[7] The therapeutic monoclonal antibody market [J].

Ecker, Dawn M. ;

Jones, Susan Dana ;

Levine, Howard L. .

MABS, 2015, 7 (01) :9-14

[8] Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing [J].

Foley, John F. ;

Goelz, Susan ;

Hoyt, Tamara ;

Christensen, Angelene ;

Metzger, Ryan R. .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 31 :65-71

[9] Evolution and Emergence of Therapeutic Monoclonal Antibodies What Cardiologists Need to Know [J].

Foltz, Ian N. ;

Karow, Margaret ;

Wasserman, Scott M. .

CIRCULATION, 2013, 127 (22) :2222-2230

[10] Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins [J].

Hamuro, Lora ;

Kijanka, Grzegorz ;

Kinderman, Francis ;

Kropshofer, Harald ;

Bu, De-xiu ;

Zepeda, Monica ;

Jawa, Vibha .

JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (10) :2946-2954

← 1 2 3 4 →